216 related articles for article (PubMed ID: 20086217)
1. Mortality in patients with pituitary disease.
Sherlock M; Ayuk J; Tomlinson JW; Toogood AA; Aragon-Alonso A; Sheppard MC; Bates AS; Stewart PM
Endocr Rev; 2010 Jun; 31(3):301-42. PubMed ID: 20086217
[TBL] [Abstract][Full Text] [Related]
2. Mortality and pituitary disease.
Stewart PM; Sherlock M
Ann Endocrinol (Paris); 2012 Apr; 73(2):81-2. PubMed ID: 22503666
[TBL] [Abstract][Full Text] [Related]
3. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly.
Sherlock M; Reulen RC; Alonso AA; Ayuk J; Clayton RN; Sheppard MC; Hawkins MM; Bates AS; Stewart PM
J Clin Endocrinol Metab; 2009 Nov; 94(11):4216-23. PubMed ID: 19808848
[TBL] [Abstract][Full Text] [Related]
4. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma.
Dekkers OM; Biermasz NR; Pereira AM; Roelfsema F; van Aken MO; Voormolen JH; Romijn JA
J Clin Endocrinol Metab; 2007 Mar; 92(3):976-81. PubMed ID: 17200171
[TBL] [Abstract][Full Text] [Related]
5. Anterior pituitary dysfunction in survivors of traumatic brain injury.
Agha A; Rogers B; Sherlock M; O'Kelly P; Tormey W; Phillips J; Thompson CJ
J Clin Endocrinol Metab; 2004 Oct; 89(10):4929-36. PubMed ID: 15472187
[TBL] [Abstract][Full Text] [Related]
6. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
Mukherjee A; Murray RD; Teasdale GM; Shalet SM
Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
[TBL] [Abstract][Full Text] [Related]
7. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis.
Mukherjee A; Murray RD; Columb B; Gleeson HK; Shalet SM
Clin Endocrinol (Oxf); 2003 Dec; 59(6):743-8. PubMed ID: 14974916
[TBL] [Abstract][Full Text] [Related]
8. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.
Tomlinson JW; Holden N; Hills RK; Wheatley K; Clayton RN; Bates AS; Sheppard MC; Stewart PM
Lancet; 2001 Feb; 357(9254):425-31. PubMed ID: 11273062
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
[TBL] [Abstract][Full Text] [Related]
10. Update in mortality in GH-treated patients.
Erfurth EM
J Clin Endocrinol Metab; 2013 Nov; 98(11):4219-26. PubMed ID: 24030944
[TBL] [Abstract][Full Text] [Related]
11. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
Webb SM; Mo D; Lamberts SW; Melmed S; Cavagnini F; Pecori Giraldi F; Strasburger CJ; Zimmermann AG; Woodmansee WW;
J Clin Endocrinol Metab; 2010 Feb; 95(2):630-8. PubMed ID: 20022992
[TBL] [Abstract][Full Text] [Related]
12. Correlation between plasma levels of ACTH and cortisol in basal states and during the CRH test in normal subjects and patients with hypothalamo-pituitary disorders.
Bando H; Zhang CY; Takada Y; Takahashi H; Yamasaki R; Saito S
Tokushima J Exp Med; 1991 Dec; 38(3-4):61-9. PubMed ID: 1668824
[TBL] [Abstract][Full Text] [Related]
13. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
[TBL] [Abstract][Full Text] [Related]
14. Potential role for retinoic acid in patients with Cushing's disease.
Pecori Giraldi F; Ambrogio AG; Andrioli M; Sanguin F; Karamouzis I; Corsello SM; Scaroni C; Arvat E; Pontecorvi A; Cavagnini F
J Clin Endocrinol Metab; 2012 Oct; 97(10):3577-83. PubMed ID: 22851491
[TBL] [Abstract][Full Text] [Related]
15. [Acromegaly and Cushing's disease: Persistence of comorbidities after the control of hypersecretion].
Rochette C; Castinetti F; Brue T
Ann Endocrinol (Paris); 2016 Oct; 77 Suppl 1():S19-S28. PubMed ID: 28645354
[TBL] [Abstract][Full Text] [Related]
16. [Report on prognosis of diencephalon-pituitary diseases].
Saito S; Yokoetsu H; Shimizu N
Nihon Naibunpi Gakkai Zasshi; 1991 Mar; 67 Suppl 2():263-76. PubMed ID: 2065811
[No Abstract] [Full Text] [Related]
17. Does acromegaly enhance mortality?
Ayuk J; Sheppard MC
Rev Endocr Metab Disord; 2008 Mar; 9(1):33-9. PubMed ID: 18075787
[TBL] [Abstract][Full Text] [Related]
18. Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
J Clin Endocrinol Metab; 2000 Nov; 85(11):4039-46. PubMed ID: 11095430
[TBL] [Abstract][Full Text] [Related]
19. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.
Jenkins PJ; Bates P; Carson MN; Stewart PM; Wass JA
J Clin Endocrinol Metab; 2006 Apr; 91(4):1239-45. PubMed ID: 16403824
[TBL] [Abstract][Full Text] [Related]
20. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease.
Suri D; Weiss RE
J Clin Endocrinol Metab; 2005 Mar; 90(3):1340-6. PubMed ID: 15585550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
